J2350Injection, ocrelizumab, 1 mg
Published CMS Medicare Part B payment-limit context for J2350, with recent quarterly history and calculated package-level strength context from the CMS crosswalk.
CMS payment limit
$60.97
per 1 MG · Medicare Part B
Up 2.3%from $59.596 in 2026-Q2
- Current quarter
- Billing unit
Payment limit over time
$61.4128$57.3642
2024-Q4: $59.798; 2025-Q1: $58.766; 2025-Q2: $57.807; 2025-Q3: $59.704; 2025-Q4: $59.414; 2026-Q1: $59.324; 2026-Q2: $59.596; 2026-Q3: $60.97
No current FDA shortage matchThe latest completed FDA data has no affected record matching the Ocrelizumab ingredient family (FDA data as of August 20, 2026).
Ocrevus
Package figures are calculated from the CMS per-unit payment limit × billable units per package; they are not CMS-published package-level payment limits.
Presentation updates
Put another code on your radar.
Browse the CMS directory for published payment-limit context across drugs, NDCs, and source-backed HCPCS Level II drug codes.